Heartflow (NASDAQ:HTFL) CEO Sells $638,730.22 in Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $28.31, for a total value of $638,730.22. Following the completion of the sale, the chief executive officer owned 436,280 shares in the company, valued at $12,351,086.80. This represents a 4.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Friday, July 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $27.75, for a total value of $626,095.50.
• On Wednesday, June 24th, John C.M. Farquhar sold 38,900 shares of Heartflow stock. The stock was sold at an average price of $35.00, for a total value of $1,361,500.00.
• On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $28.50, for a total value of $643,017.00.

Heartflow Price Performance

Shares of Heartflow stock opened at $42.08 on Friday. The business has a fifty day simple moving average of $29.08 and a two-hundred day simple moving average of $27.80. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $43.00. The company has a market capitalization of $3.63 billion and a price-to-earnings ratio of -22.99.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. The firm had revenue of $64.08 million for the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.50%. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. As a group, equities analysts anticipate that Heartflow, Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Heartflow

A number of institutional investors have recently bought and sold shares of HTFL. Caitong International Asset Management Co. Ltd acquired a new position in shares of Heartflow during the 4th quarter worth approximately $27,000. Russell Investments Group Ltd. acquired a new stake in shares of Heartflow in the fourth quarter valued at approximately $45,000. Essential Partners LLC bought a new stake in shares of Heartflow in the first quarter valued at approximately $57,000. Legal & General Group Plc bought a new stake in shares of Heartflow in the third quarter valued at approximately $59,000. Finally, Strs Ohio acquired a new stake in Heartflow during the fourth quarter worth approximately $99,000.

Key Headlines Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Heartflow reported second-quarter revenue of $64.1 million, up 47.7% year over year, while its adjusted loss of $0.07 per share beat the consensus estimate of a $0.22 loss. The results also showed improving profitability, with adjusted EBITDA losses narrowing to $6.7 million from $10.1 million a year earlier. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $246 million-$250 million from $228 million-$232 million, above the roughly $230 million analyst consensus, and projected non-GAAP gross margin of about 82%. HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
• Positive Sentiment: Growth was supported by stronger U.S. FFRCT volume and increasing adoption of the Plaque product, suggesting Heartflow’s AI-based coronary disease platform is broadening beyond its core business.
• Positive Sentiment: Analysts raised their targets following the report: JPMorgan increased its target to $45 and Stifel raised its target to $45, with both firms maintaining bullish ratings. Wells Fargo also raised its target to $39 and retained an “overweight” rating. Analyst Price Target Updates
• Neutral Sentiment: The strong move pushed the stock near its 52-week high, potentially increasing volatility and making valuation a greater consideration for investors despite improving operating trends.
• Negative Sentiment: Insiders have reported repeated open-market sales, including a 22,562-share sale by CEO John C.M. Farquhar. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but continued insider selling may still weigh on sentiment. Heartflow CEO Sells Shares

Analyst Ratings Changes

HTFL has been the topic of several research analyst reports. William Blair initiated coverage on shares of Heartflow in a report on Monday, May 4th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. upped their target price on Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research report on Friday. Freedom Capital upgraded Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. Morgan Stanley lifted their price target on Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Friday. Finally, Benchmark restated a “buy” rating on shares of Heartflow in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.43.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.